<SEC-DOCUMENT>0001393905-19-000001.txt : 20190109
<SEC-HEADER>0001393905-19-000001.hdr.sgml : 20190109
<ACCEPTANCE-DATETIME>20190109115553
ACCESSION NUMBER:		0001393905-19-000001
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190108
FILED AS OF DATE:		20190109
DATE AS OF CHANGE:		20190109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	CRUDE PETROLEUM & NATURAL GAS [1311]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30314
		FILM NUMBER:		19517698

	BUSINESS ADDRESS:	
		STREET 1:		47 AVENUE ROAD
		STREET 2:		SUITE 200
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5R 2G3
		BUSINESS PHONE:		416-929-1806

	MAIL ADDRESS:	
		STREET 1:		47 AVENUE ROAD
		STREET 2:		SUITE 200
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5R 2G3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ptgef_6k.htm
<DESCRIPTION>REPORT OF FOREIGN ISSUER
<TEXT>
<HTML>
<head><title>6K</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; COLOR:#000000; MARGIN-TOP:0px"> <p style=MARGIN:0px align=center><br></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>UNITED STATES</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>SECURITIES AND EXCHANGE COMMISSION</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>Washington, D.C. 20549</b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:18pt; MARGIN:0px" align=center><b>Form 6-K</b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>For the month of January 2019</p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(January 8, 2019)</p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>Commission File Number 0-30314</p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:18pt; MARGIN:0px" align=center><b>PORTAGE BIOTECH INC.</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Translation of registrant's name into English)</p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>47 Avenue Rd., Suite 200, Toronto, Ontario, Canada M5R 2G3</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Address of principal executive office)</p> <p style=MARGIN:0px align=center><br></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. &nbsp;Form 20-F [X] &nbsp;Form 40-F [ &nbsp;]</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ &nbsp;]</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ &nbsp;]</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. &nbsp;Yes [ &nbsp;] &nbsp;No [X]</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): &nbsp;82- ______________.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br><br></p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <p style="PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify><br></p> <p style="FONT-SIZE:14pt; MARGIN:0px" align=center><b>Shareholders approve Acquisition of SalvaRx Limited</b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Toronto, Ontario, January 8, 2019 (PBT.U: CSE, PTGEF: OTC Markets) &#150; Portage Biotech Inc. ("Portage" or the "Company") is very pleased to announce that, at an annual general special meeting held today, shareholders overwhelmingly approved the acquisition of SalvaRx Limited (the &#147;Transaction&#148;) along with other matters including the election of directors. Details of the Transaction are contained in the Company&#146;s information circular dated November 26th, 2018 and its news release dated December 19, 2018 providing supplemental information regarding the Independent Director Review of the Transaction, copies of which may be found on www.sedar.com and the Company&#146;s website: https://www.portagebiotech.com/.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>The Transaction also received minority shareholder approval in accordance with Multilateral Instrument 61-101 </font><font style=BACKGROUND-COLOR:#ffffff><i>Protection of Minority Security Holders in Special Transactions</i></font><font style=BACKGROUND-COLOR:#ffffff>.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Other matters approved at the meeting include: (a) the re-election of Declan Doogan, Kam Shah, Gregory Bailey, James Mellon, Steven Mintz and Ian Walters as directors; (b) the appointment of auditors; (c) the 2018 Consultant Stock Compensation Plan; (d) the 2018 Stock Option Plan; and (e) advance approval for a stock consolidation to be effected at such time as the directors in their discretion deem appropriate.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>In accordance with the terms of the Share Purchase Agreement dated August 13, 2018, Portage will be issuing an aggregate of 805,070,066 common shares (the &#147;Consideration Shares&#148;) on January 9, 2018 as follows:</font></p> <p style=MARGIN:0px align=justify><br></p> <table bordercolor=transparent style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0 align=center> <tr style=FONT-SIZE:0px> <td width=269> <td width=279 /> </tr><tr> <td width=269 style="BORDER-BOTTOM:#000000 1px solid; MARGIN-TOP:0px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><b>Seller</b></p></td> <td width=279 style="BORDER-BOTTOM:#000000 1px solid; MARGIN-TOP:0px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><b>Number of Consideration Shares</b></p></td></tr> <tr> <td width=269 style="MARGIN-TOP:0px; BACKGROUND-COLOR:#dbe5f1" valign=top><p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>SalvaRx Group plc</p></td> <td width=279 style="MARGIN-TOP:0px; BACKGROUND-COLOR:#dbe5f1" valign=top><p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>757,943,784</p></td></tr> <tr> <td width=269 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>James Mellon</p></td> <td width=279 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>23,563,141</p></td></tr> <tr> <td width=269 style="MARGIN-TOP:0px; BACKGROUND-COLOR:#dbe5f1" valign=top><p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>Gregory Bailey</p></td> <td width=279 style="MARGIN-TOP:0px; BACKGROUND-COLOR:#dbe5f1" valign=top><p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>23,563,141</p></td></tr></table> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Upon receipt of its Consideration Shares, SalvaRx Group plc (&#147;Group&#148;) (AIM: SALV) intends to distribute the bulk of them to its shareholders as part of a corporate re-organization. Further information may be found at Group&#146;s website: https://www.salvarx.io/.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>To obtain final CSE approval, the Company will be preparing and filing a Form 2A with CSE which will provide prospectus level disclosure on the Company after giving effect to the Transaction.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Greg Bailey MD, Chairman of Portage, said:</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>&#147;As we have seen with the recent acquisition of Celgene for $74 billion based predominantly on its oncology pipeline this remains a very exciting area. We feel that the Portage/SalvaRx transaction positions both companies for the next phase of development. Both companies will continue their business models of building tangible businesses. I want to thank our shareholders for their patience as we waited for routine approvals.&#148;</font></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br><br></p> <p style="FONT-SIZE:8pt; MARGIN:0px" align=center>2</p> <p style=MARGIN:0px align=justify><br></p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <p style="PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>For further information, please contact:</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Kam Shah, CFO</font></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Tel: (416) 929-1806</font></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>ks@portagebiotech.com</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff><i>Neither CSE nor its Market Regulator (as the term is defined in the policies of CSE) accepts responsibility for the adequacy or accuracy of this release.</i></font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff><i>This news release may contain forward looking statements concerning future operations of</i></font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff><i>Portage Biotech Inc. (the "Company"). All forward looking statements concerning the Company&#146;s future plans and operations, including management&#146;s assessment of the Company&#146;s expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company&#146;s control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates and projections.</i></font></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=center><br><br></p> <p style="FONT-SIZE:8pt; MARGIN:0px" align=center>3</p> <p style=MARGIN:0px align=justify><br></p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <p style="PAGE-BREAK-BEFORE:always; MARGIN:0px" align=center><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><font style=BACKGROUND-COLOR:#ffffff><b>SIGNATURES</b></font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Dated: &nbsp;January 8, 2019</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>PORTAGE BIOTECH INC.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>By: </font><font style=BACKGROUND-COLOR:#ffffff><i><u>/s/ Kam Shah</u></i></font></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Kam Shah</font></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify><font style=BACKGROUND-COLOR:#ffffff>Chief Financial Officer</font></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br><br></p> <p style="FONT-SIZE:8pt; MARGIN:0px" align=center>4</p> <p style=MARGIN:0px align=justify><br></p></body>
<!-- EDGAR Validation Code: 2EE1D56C -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
